Security key
86150R107
Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK)
CUSIP: 86150R107
Q4 2024 13F Holders as of 31 Dec 2024
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Total 13F shares
- 58,062,255
- Total 13F value
- $640,428,361
- Share change
- -112,954
- Put/Call ratio
- 793%
- SEC-reported price per share
- $11.03
- Number of holders
- 129
- Value change
- -$5,638,079
- Number of buys
- 62
- Number of sells
- 55
- Shares outstanding
- 58,810,778
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2024
Institutions
129
Top holders
10
STOK full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2025
Previous quarter: Q3 2024
Stoke Therapeutics, Inc. SEC filings
Stoke Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 86150R107
Recent filing periods:
Ownership snapshot
Top reported holders of STOK - Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
MORGAN STANLEY
Disclosed value leader
Skorpios Trust
Comparable rows
15/15
Latest evidence
30 Sep 2024
13F
13D/G
Lead comparable stake: 6.5%
13D/G row: MORGAN STANLEY
Showing 1-6 of 15 holder rows.
Quick read
MORGAN STANLEY leads the comparable SEC ownership view at 6.5%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens MORGAN STANLEY's linked filing trail.
Comparable ownership
Top 5
MORGAN STANLEY
6.5%
Skorpios Trust
15%
BlackRock, Inc.
9.5%
Lynx1 Capital Management LP
8.8%
Redmile Group, LLC
8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| MORGAN STANLEY |
13F
13D/G
Company
|
6.5%
from 13D/G
|
$51,683,223
4,205,307 shares
|
— | 30 Sep 2024 |
| Skorpios Trust |
13F
Company
|
15%
|
$109,456,964
8,906,181 shares
|
— | 30 Sep 2024 |
| BlackRock, Inc. |
13F
Company
|
9.5%
|
$68,457,143
5,570,150 shares
|
— | 30 Sep 2024 |
| Lynx1 Capital Management LP |
13F
Company
|
8.8%
|
$63,750,577
5,187,191 shares
|
— | 30 Sep 2024 |
| Redmile Group, LLC |
13F
Company
|
8%
|
$57,929,026
4,713,509 shares
|
— | 30 Sep 2024 |
| RTW INVESTMENTS, LP |
13F
Company
|
7.9%
|
$57,176,583
4,652,285 shares
|
— | 30 Sep 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
129
Shares
58,062,255
Rows available
129
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
116
Q4 2024 holders
129
Holder diff
13
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 value | Q4 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend